TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical gadget firm that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2022 monetary outcomes after market shut on Thursday, November 3, 2022.
Profound administration will host a convention name at 4:30 p.m. ET to assessment the monetary outcomes and focus on business developments within the interval.
The name may also be broadcast dwell and archived on the Company’s web site at www.profoundmedical.com beneath “Webcasts” within the Investors part.
About Profound Medical Corp.
Profound is a commercial-stage medical gadget firm that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a know-how that mixes real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature suggestions management. TULSA-PRO® is designed to present customizable and predictable radiation-free ablation of a surgeon-defined prostate quantity whereas actively defending the urethra and rectum to assist protect the affected person’s pure purposeful talents. TULSA-PRO® has the potential to be a versatile know-how in customizable prostate ablation, together with intermediate stage most cancers, localized radio-recurrent most cancers, retention and hematuria palliation in regionally superior prostate most cancers, and the transition zone in massive quantity benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada accepted, and 510(ok) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound can be commercializing Sonalleve®, an revolutionary therapeutic platform that’s CE marked for the therapy of uterine fibroids and palliative ache therapy of bone metastases. Sonalleve® has additionally been accepted by the China National Medical Products Administration for the non-invasive therapy of uterine fibroids and has FDA approval beneath a Humanitarian Device Exemption for the therapy of osteoid osteoma. The Company is within the early phases of exploring extra potential therapy markets for Sonalleve® the place the know-how has been proven to have scientific software, equivalent to non-invasive ablation of belly cancers and hyperthermia for most cancers remedy.
For additional info, please contact:
Stephen Kilmer
Investor Relations
[email protected]
T: 647.872.4849
